Table 2.
CD4 Sample (n= 21,999) | Test for Trend p-value | ||
---|---|---|---|
Baseline AUDIT-C Score | N | Mean (SD) Baseline CD4 | <0.001 |
0 | 10372 | 511.3 (303.8) | |
1–3 (1–2 for women) | 8760 | 516.7 (293.6) | |
4–5 (3–5 for women) | 1676 | 506.0 (284.2) | |
6–7 | 512 | 504.2 (313.5) | |
8–12 | 679 | 434.7 (278.0) | |
Viral Load Sample (n=22,143) | |||
Baseline AUDIT-C Score | N | Mean (SD) Baseline logVL** | <0.001 |
0 | 10434 | 2.97 (0.68) | |
1–3 (1–2 for women) | 8828 | 3.03 (0.74) | |
4–5 (3–5 for women) | 1705 | 3.06 (0.74) | |
6–7 | 502 | 3.11 (0.80) | |
8–12 | 674 | 3.26 (0.88) | |
N (%) with Detectable VL | <0.001 | ||
0 | 10434 | 1,979 (19.0) | |
1–3 (1–2 for women) | 8828 | 2,011 (22.8) | |
4–5 (3–5 for women) | 1705 | 447 (26.2) | |
6–7 | 502 | 149 (29.7) | |
8–12 | 674 | 246 (36.5) |
Analyses were conducted at the patient (as opposed to the observation) level
Estimates for baseline logVL are high relative to current targets for suppression (<1.7 logs / < 50); viral suppression in the present study was at <2.7 logs / <500 copies/ml.